{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:29:44Z","timestamp":1786649384434,"version":"build-2736575974"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["J Int Soc Prev Community Dent"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>bstract<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Oral squamous cell carcinoma (OSCC) continues to pose significant therapeutic challenges due to high recurrence rates and treatment-related toxicity. Drug repurposing offers an accelerated, cost-effective pathway to discover novel therapeutic indications for established medications. This narrative review evaluates the mechanistic rationale and clinical potential of repurposing antifungal agents, such as azoles and allylamines, as adjuvant therapies for OSCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A comprehensive literature search was performed across PubMed and Scopus (up to November 14, 2025). Studies were selected based on their focus on antifungal-mediated inhibition of OSCC growth and metastasis. Methodological quality was assessed using the Scale for the Evaluation of Narrative Review Articles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Antifungal agents, particularly itraconazole and terbinafine, exhibit potent antitumor activity by targeting key oncogenic pathways, including the Sonic Hedgehog (SHH) and phosphatidylinositol 3-kinase\/protein kinase B\/mammalian target of rapamycin signaling axes. Preclinical evidence indicates that these agents induce apoptosis, inhibit angiogenesis, and sensitize OSCC cells to standard chemotherapy and radiotherapy. Specifically, itraconazole shows promise in treating SHH-high tumors, while terbinafine reduces tumor proliferation through antiangiogenic mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Antifungal drugs represent a biologically viable and resource-efficient strategy for enhancing OSCC treatment outcomes. To maximize clinical translation, future research must prioritize the development of nanoformulations and liposomal azoles to overcome existing bioavailability limitations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jispcd.jispcd_187_25","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T22:00:08Z","timestamp":1777154408000},"page":"238-248","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Repurposing Antifungal Drugs for Oral Cancer Treatment: Mechanistic Insights and Clinical Potential\u2014A Narrative Review"],"prefix":"10.4103","volume":"16","author":[{"given":"Anju","family":"Mayadevi Nair","sequence":"first","affiliation":[{"name":"Department of Oral Medicine and Radiology, Sri Ramachandra Dental College and Hospital, Sri Ramachandra Institute of Higher Education and Research (DU), Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bounika","family":"Esvanth Rao","sequence":"additional","affiliation":[{"name":"Department of Oral Medicine and Radiology, Sri Ramachandra Dental College and Hospital, Sri Ramachandra Institute of Higher Education and Research (DU), Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish Srinivas","family":"Kondaveeti","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sri Ramachandra Medical College and Research Institute, Sri Ramachandra Institute of Higher Education and Research (DU), Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhi Venkatshree","family":"Anand Kumar","sequence":"additional","affiliation":[{"name":"Department of Oral Medicine and Radiology, Sri Ramachandra Dental College and Hospital, Sri Ramachandra Institute of Higher Education and Research (DU), Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruwan D.","family":"Jayasinghe","sequence":"additional","affiliation":[{"name":"Department of Oral Medicine and Periodontology, Faculty of Dental Sciences, University of Peradeniya, Peradeniya, Sri Lanka"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayalakshmi","family":"Ramshankar","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology and Molecular Diagnostics, Cancer Institute (WIA), Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyambika","family":"Catakapatri Venugopal","sequence":"additional","affiliation":[{"name":"Department of Oral Medicine and Radiology, Sri Ramachandra Dental College and Hospital, Sri Ramachandra Institute of Higher Education and Research (DU), Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"CIT0001-20260626","doi-asserted-by":"crossref","first-page":"379","DOI":"10.31557\/apjcb.2023.8.4.379-386","article-title":"Oral cancer at a glance","volume":"8","author":"Saberian","year":"2023","journal-title":"Asian Pac J Cancer Biol"},{"key":"CIT0002-20260626","article-title":"Global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2022","volume":"76","author":"Rumgay","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"CIT0003-20260626","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/cac2.12009","article-title":"Global and regional burdens of oral cancer from 1990 to 2017: Results from the global burden of disease study","volume":"40","author":"Ren","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"CIT0004-20260626","first-page":"42","article-title":"Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma","volume":"11","author":"Barsouk","year":"2023","journal-title":"Med Sci"},{"key":"CIT0005-20260626","doi-asserted-by":"crossref","first-page":"e389810","DOI":"10.1200\/EDBK_389810","article-title":"Current treatment strategies and risk stratification for oral carcinoma","volume":"43","author":"Mohamad","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"CIT0006-20260626","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3390\/pharmaceutics16111420","article-title":"Enhancing cancer treatment through combined approaches: Photodynamic therapy in concert with other modalities","volume":"16","author":"Hong","year":"2024","journal-title":"Pharmaceutics"},{"key":"CIT0007-20260626","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0360-3016(99)00553-2","article-title":"Local and distant failures after limited surgery with positive margins and radiotherapy for node-negative breast cancer","volume":"47","author":"Cowen","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"CIT0008-20260626","doi-asserted-by":"crossref","first-page":"117695","DOI":"10.1016\/j.lfs.2020.117695","article-title":"Anti-fungal drug itraconazole exerts anti-cancer effects in oral squamous cell carcinoma via inhibiting the Hedgehog pathway","volume":"254","author":"Ban","year":"2020","journal-title":"Life Sci"},{"key":"CIT0009-20260626","doi-asserted-by":"crossref","first-page":"563838","DOI":"10.3389\/fonc.2020.563838","article-title":"Inhibition of CAL27 oral squamous carcinoma cell by targeting hedgehog pathway with vismodegib or itraconazole","volume":"10","author":"Freitas","year":"2020","journal-title":"Front Oncol"},{"key":"CIT0010-20260626","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/mc.20800","article-title":"Terbinafine inhibits oral squamous cell carcinoma growth through anti-cancer cell proliferation and anti-angiogenesis","volume":"51","author":"Chien","year":"2012","journal-title":"Mol Carcinog"},{"key":"CIT0011-20260626","doi-asserted-by":"crossref","first-page":"406","DOI":"10.4149\/neo_2013_052","article-title":"Terbinafine inhibits KSR1 and suppresses Raf-MEK-ERK signaling in oral squamous cell carcinoma cells","volume":"60","author":"Li","year":"2013","journal-title":"Neoplasma"},{"key":"CIT0012-20260626","doi-asserted-by":"crossref","first-page":"e98885","DOI":"10.1371\/journal.pone.0098885","article-title":"The in vitro and in vivo antitumor effects of clotrimazole on oral squamous cell carcinoma","volume":"9","author":"Wang","year":"2014","journal-title":"PLoS One"},{"key":"CIT0013-20260626","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014A scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integr Peer Rev"},{"key":"CIT0014-20260626","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.tox.2006.08.007","article-title":"Comparison of lanosterol-14 alpha-demethylase (CYP51) of human and Candida albicans for inhibition by different antifungal azoles","volume":"228","author":"Tr\u00f6sken","year":"2006","journal-title":"Toxicology"},{"key":"CIT0015-20260626","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1042\/bj2660475","article-title":"Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans","volume":"266","author":"Hitchcock","year":"1990","journal-title":"Biochem J"},{"key":"CIT0016-20260626","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1128\/CMR.12.4.501","article-title":"Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance","volume":"12","author":"Ghannoum","year":"1999","journal-title":"Clin Microbiol Rev"},{"key":"CIT0017-20260626","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s12088-017-0657-1","article-title":"Recent advances in ergosterol biosynthesis and regulation mechanisms in saccharomyces cerevisiae","volume":"57","author":"Hu","year":"2017","journal-title":"Indian J Microbiol"},{"key":"CIT0018-20260626","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2133.1992.tb00001.x","article-title":"Terbinafine: Mode of action and properties of the squalene epoxidase inhibition","volume":"126","author":"Ryder","year":"1992","journal-title":"Br J Dermatol"},{"key":"CIT0019-20260626","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/cncr.31063","article-title":"Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma","volume":"124","author":"Gleber-Netto","year":"2018","journal-title":"Cancer"},{"key":"CIT0020-20260626","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"CIT0021-20260626","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","article-title":"Targeting p53 pathways: Mechanisms, structures and advances in therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"CIT0022-20260626","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: From molecular mechanism to therapeutic modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"key":"CIT0023-20260626","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4161\/cc.23054","article-title":"Wild-type and mutant p53 mediate cisplatin resistance through interaction and inhibition of active caspase-9","volume":"12","author":"Chee","year":"2013","journal-title":"Cell Cycle"},{"key":"CIT0024-20260626","first-page":"1150","article-title":"Oxidative stress in the pathogenesis of oral cancer","volume":"12","author":"Ionescu","year":"2024","journal-title":"Biomed"},{"key":"CIT0025-20260626","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.cpt.2025.03.004","article-title":"Clotrimazole as a new frontier: Drug repurposing and its efficacy in cancer therapy","volume":"4","author":"Karpe","year":"2025","journal-title":"Cancer Pathog Ther"},{"key":"CIT0026-20260626","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/AAC.35.4.707","article-title":"High-dose itraconazole in the treatment of severe mycoses","volume":"35","author":"Sharkey","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"CIT0027-20260626","doi-asserted-by":"crossref","first-page":"435","DOI":"10.5005\/jp-journals-10015-1686","article-title":"Immunohistochemical expression of epidermal growth factor receptor among metastatic and nonmetastatic oral squamous cell carcinomas","volume":"10","author":"Indrapriyadharshini","year":"2019","journal-title":"World J Dent"},{"key":"CIT0028-20260626","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41368-023-00249-w","article-title":"Oral squamous cell carcinomas: State of the field and emerging directions","volume":"15","author":"Tan","year":"2023","journal-title":"Int J Oral Sci"},{"key":"CIT0029-20260626","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers"},{"key":"CIT0030-20260626","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1002\/hed.28152","article-title":"Phase II trial of chemotherapy, cetuximab, and erlotinib in patients with metastatic or recurrent squamous cell carcinoma of the head and neck","volume":"47","author":"Bhatia","year":"2025","journal-title":"Head Neck"},{"key":"CIT0031-20260626","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.3390\/cancers15205009","article-title":"Resistance of lung cancer to egfr-specific kinase inhibitors: Activation of bypass pathways and endogenous mutators","volume":"15","author":"Marrocco","year":"2023","journal-title":"Cancers"},{"key":"CIT0032-20260626","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.3390\/cancers14051286","article-title":"PIK3CA gene mutations in HNSCC: Systematic review and correlations with HPV status and patient survival","volume":"14","author":"Cochicho","year":"2022","journal-title":"Cancers (Basel)"},{"key":"CIT0033-20260626","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ccr.2010.02.027","article-title":"Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth","volume":"17","author":"Kim","year":"2010","journal-title":"Cancer Cell"},{"key":"CIT0034-20260626","first-page":"1610","article-title":"The role of the PI3K\/Akt\/TOR axis in head and neck squamous cell carcinoma","volume":"12","author":"Jiang","year":"2024","journal-title":"Biomed"},{"key":"CIT0035-20260626","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12943-018-0803-3","article-title":"PTEN\/PTENP1: \u2018Regulating the regulator of RTK-dependent PI3K\/Akt signalling\u2019, new targets for cancer therapy","volume":"17","author":"Haddadi","year":"2018","journal-title":"Mol Cancer"},{"key":"CIT0036-20260626","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/bcr3039","article-title":"Mutations in the phosphatidylinositol 3-kinase pathway: Role in tumor progression and therapeutic implications in breast cancer","volume":"13","author":"Miller","year":"2011","journal-title":"Breast Cancer Res"},{"key":"CIT0037-20260626","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0092-8674(00)80405-5","article-title":"Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery","volume":"91","author":"Datta","year":"1997","journal-title":"Cell"},{"key":"CIT0038-20260626","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.cmet.2014.03.018","article-title":"Grb10 promotes lipolysis and thermogenesis by phosphorylation-dependent feedback inhibition of mTORC1","volume":"19","author":"Liu","year":"2014","journal-title":"Cell Metab"},{"key":"CIT0039-20260626","doi-asserted-by":"crossref","first-page":"5844","DOI":"10.3390\/ijms26125844","article-title":"Functional analysis of the PI3K\/AKT\/mTOR pathway inhibitor, gedatolisib, plus fulvestrant with and without palbociclib in breast cancer models","volume":"26","author":"Broege","year":"2025","journal-title":"Int J Mol Sci"},{"key":"CIT0040-20260626","doi-asserted-by":"crossref","first-page":"6853","DOI":"10.3390\/ijms26146853","article-title":"The role of PI3K\/AKT\/mTOR signaling in tumor radioresistance and advances in inhibitor research","volume":"26","author":"Zhan","year":"2025","journal-title":"Int J Mol Sci"},{"key":"CIT0041-20260626","doi-asserted-by":"crossref","first-page":"68641","DOI":"10.18632\/oncotarget.19817","article-title":"Targeting the PI3K\/AKT\/mTOR signaling pathway as an effectively radiosensitizing strategy for treating human oral squamous cell carcinoma in vitro and in vivo","volume":"8","author":"Yu","year":"2017","journal-title":"Oncotarget"},{"key":"CIT0042-20260626","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.3390\/cancers14133160","article-title":"Dual PI3K\/mTOR inhibitor NVP-BEZ235 leads to a synergistic enhancement of cisplatin and radiation in both HPV-negative and -positive HNSCC cell lines","volume":"14","author":"Subtil FS","year":"2022","journal-title":"Cancers"},{"key":"CIT0043-20260626","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1158\/0008-5472.CAN-18-1220","article-title":"4E-BP1 is a tumor suppressor protein reactivated by mTOR inhibition in head and neck cancer","volume":"79","author":"Wang","year":"2019","journal-title":"Cancer Res"},{"key":"CIT0044-20260626","doi-asserted-by":"crossref","first-page":"15749","DOI":"10.3390\/ijms232415749","article-title":"Targeting PI3K\/AKT\/mTOR signaling pathway as a radiosensitization in head and neck squamous cell carcinomas","volume":"23","author":"Su","year":"2022","journal-title":"Int J Mol Sci"},{"key":"CIT0045-20260626","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/sj.bjc.6604290","article-title":"Inhibition of ICAM2 induces radiosensitisation in oral squamous cell carcinoma cells","volume":"98","author":"Ishigami","year":"2008","journal-title":"Br J Cancer"},{"key":"CIT0046-20260626","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3390\/cells9030533","article-title":"Circumventing AKT-associated radioresistance in oral cancer by novel nanoparticle-encapsulated capivasertib","volume":"9","author":"Lang","year":"2020","journal-title":"Cells"},{"key":"CIT0047-20260626","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1128\/AAC.02067-12","article-title":"Azole affinity of sterol 14\u03b1-demethylase (CYP51) enzymes from Candida albicans and Homo sapiens","volume":"57","author":"Warrilow","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"CIT0048-20260626","doi-asserted-by":"crossref","first-page":"e0167485","DOI":"10.1371\/journal.pone.0167485","article-title":"Structural and functional elucidation of yeast lanosterol 14\u03b1-demethylase","volume":"11","author":"Tyndall","year":"2016","journal-title":"PLoS One"},{"key":"CIT0049-20260626","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.3390\/cancers14143368","article-title":"Drug repurposing to enhance antitumor response to PD-1\/PD-L1 immune checkpoint inhibitors","volume":"14","author":"Thuru","year":"2022","journal-title":"Cancers (Basel)"},{"key":"CIT0050-20260626","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.joms.2014.12.030","article-title":"Vascular endothelial growth factor receptor isoforms: Are they present in oral squamous cell carcinoma?","volume":"73","author":"Pianka","year":"2015","journal-title":"J Oral Maxillofac Surg"},{"key":"CIT0051-20260626","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jobcr.2023.07.002","article-title":"A. Prostaglandin-endoperoxide synthase 2 (PTGS2) gene expression and its association with genes regulating the VEGF signaling pathway in head and neck squamous cell carcinoma","volume":"13","author":"Kamal","year":"2023","journal-title":"J Oral Biol Craniofac Res"},{"key":"CIT0052-20260626","doi-asserted-by":"crossref","first-page":"118023","DOI":"10.1016\/j.biopha.2025.118023","article-title":"Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: Therapeutic strategies and insights","volume":"186","author":"Mahaki","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"CIT0053-20260626","doi-asserted-by":"crossref","first-page":"210","DOI":"10.21037\/tcr-20-2498","article-title":"Co-expression of VEGF-C and survivin predicts poor prognosis in esophageal squamous cell carcinoma","volume":"10","author":"Zeng","year":"2020","journal-title":"Transl Cancer Res"},{"key":"CIT0054-20260626","first-page":"4429","article-title":"Immunohistochemical study of VEGF expression in oral squamous cell carcinomas: Correlation with the mTOR\u2013HIF-1\u03b1 pathway","volume":"31","author":"Naruse","year":"2011","journal-title":"Anticancer Res"},{"key":"CIT0055-20260626","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/08977199209023937","article-title":"The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies","volume":"7","author":"Kim","year":"1992","journal-title":"Growth Factors"},{"key":"CIT0056-20260626","first-page":"4593","article-title":"Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders","volume":"57","author":"Presta","year":"1997","journal-title":"Cancer Res"},{"key":"CIT0057-20260626","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/cncr.24009","article-title":"Sequential therapy with sorafenib and sunitinib in renal cell carcinoma","volume":"115","author":"Dudek","year":"2008","journal-title":"Cancer"},{"key":"CIT0058-20260626","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1007\/s00432-004-0654-8","article-title":"Matrix metalloproteinases 2 and 9 in oral squamous cell carcinomas: Manifestation and localization of their activity","volume":"131","author":"Kato","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"key":"CIT0059-20260626","doi-asserted-by":"crossref","first-page":"14351","DOI":"10.1038\/s41598-023-41514-6","article-title":"TNF\u03b1 induces matrix metalloproteinase-9 expression in monocytic cells through ACSL1\/JNK\/ERK\/NF-kB signaling pathways","volume":"13","author":"Akhter","year":"2023","journal-title":"Sci Rep"},{"key":"CIT0060-20260626","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1182\/blood.V94.6.2080","article-title":"Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin\u2019s lymphomas","volume":"94","author":"Kossakowska","year":"1999","journal-title":"Blood"},{"key":"CIT0061-20260626","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1111\/cas.14432","article-title":"Miconazole inhibits signal transducer and activator of transcription 3 signalling by preventing its interaction with DNA damage-induced apoptosis suppressor","volume":"111","author":"Yoon","year":"2020","journal-title":"Cancer Sci"},{"key":"CIT0062-20260626","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3332\/ecancer.2015.521","article-title":"Repurposing drugs in oncology (ReDO)-itraconazole as an anti-cancer agent","volume":"9","author":"Pantziarka","year":"2015","journal-title":"Ecancermedicalscience"},{"key":"CIT0063-20260626","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1128\/AAC.48.1.216-223.2004","article-title":"Intracutaneous distributions of fluconazole, itraconazole, and griseofulvin in Guinea pigs and binding to human stratum corneum","volume":"48","author":"Sobue","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"CIT0064-20260626","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s13555-019-0299-9","article-title":"Itraconazole in the treatment of nonfungal cutaneous diseases: A review","volume":"9","author":"Tsai","year":"2019","journal-title":"Dermatol Ther (Heidelb)"},{"key":"CIT0065-20260626","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4103\/ijd.IJD_191_17","article-title":"Efficacy and safety of terbinafine 500\u2009mg once daily in patients with dermatophytosis","volume":"62","author":"Babu","year":"2017","journal-title":"Indian J Dermatol"},{"key":"CIT0066-20260626","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1128\/AAC.46.7.2219-2228.2002","article-title":"Physiologically based pharmacokinetic model for terbinafine in rats and humans","volume":"46","author":"Hosseini-Yeganeh","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"CIT0067-20260626","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1158\/1535-7163.MCT-06-0457","article-title":"Terbinafine inhibits endothelial cell migration through suppression of the rho-mediated pathway","volume":"5","author":"Ho","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"CIT0068-20260626","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.prostaglandins.2016.06.002","article-title":"EETs and HO-1 cross-talk","volume":"125","author":"Sacerdoti","year":"2016","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"CIT0069-20260626","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00280-011-1693-x","article-title":"Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor","volume":"68","author":"Hamberg","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"CIT0070-20260626","doi-asserted-by":"crossref","first-page":"10200","DOI":"10.1038\/s41598-021-89655-w","article-title":"Repurposing ketoconazole as an exosome-directed adjunct to sunitinib in treating renal cell carcinoma","volume":"11","author":"Greenberg","year":"2021","journal-title":"Sci Rep"}],"container-title":["Journal of International Society of Preventive and Community Dentistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jispcd.jispcd_187_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:53:26Z","timestamp":1786647206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jispcd.jispcd_187_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/jispcd.jispcd_187_25","relation":{},"ISSN":["2231-0762","2250-1002"],"issn-type":[{"value":"2231-0762","type":"print"},{"value":"2250-1002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"2025-10-24","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}